Oncology Portfolio Articles & Analysis
15 news found
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer ...
ByBayer AG
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. ...
The financing will be used to advance NextPoint’s two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. ...
ByBayer AG
Focusing on our strategic therapeutic areas, we strive to push forward our deep, differentiated portfolio in immunology, build out our oncology franchise, and execute on business development opportunities with the aim to accelerate innovation and speed up time-to-patients, while creating long-term value for our ...
He previously held several senior leadership roles where he executed significant transactions in oncology and cellular therapy, including leading the Leukemia & Lymphoma Society’s Therapy Acceleration Program (TAP). ...
The data were presented in a poster presentation (abstract #2517) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. “We’re pleased to report the positive Phase 1 data on our novel arenaviral immunotherapies for advanced head and neck cancers, which highlight the ability of our platform technology to induce a high magnitude of potent, ...
(“OnkosXcel”) to develop transformative medicines in oncology. OnkosXcel is focused on the sustained expansion and optimization of the oncology franchise, while providing maximum strategic and financial flexibility. ...
The YoY growth of 7% was driven mainly by the Everolimus launch, and we expect this product to continue to contribute to the growth of our generic formulation portfolio. COVID related disruptions that had impacted our operations earlier in the fiscal began to abate during this quarter as we saw a return to normalcy. ...
ByBiocon
About Alkermes plc Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative ...
ByAlkermes
He was also Chairman of the Novartis Oncology Portfolio Management Board. Dr Filipovic obtained his PhD in Biochemistry and Biophysics from the Swiss Federal Institute of Technology (ETH) in Zürich. ...
Today, Thermo Fisher Scientific announces a new portfolio of hematology-oncology assays for the Ion Torrent Genexus System* designed to enable a future in which turnaround times for next-generation sequencing (NGS) results can be reduced to less than 24 hours. ...
This agreement extends the radio-oncology portfolio of Debiopharm which currently includes another clinical stage radiotherapeutic and the radiotherapy-enhancing antagonist of lAPs (Inhibitors of Apoptosis proteins) Debio 1143. ...
Delivering on that need will mean that hematology and oncology labs can quickly get the results they need." Expanded Portfolio Addresses Full Range of Hematology Applications Thermo Fisher also announced an expanded portfolio of NGS-based hematology-oncology research assays that make it easier to assess lymphoid malignancies. ...
The siRNA molecules have now progressed to in vivo studies. Dr. Lee Chapman, Head of Oncology at Celixir, said: “These early results are promising and highlight the potential of Celixir’s oncology gene therapy pipeline to aid in the treatment of two of the most serious cancers, colon cancer and breast ...
Hyderabad, India, 17th January 2019: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. ...